Literature DB >> 24173221

Hepatocyte nuclear factor 4α and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus.

Xinlei Li1, Hanfang Jiang, Linbing Qu, Wenxia Yao, Hua Cai, Ling Chen, Tao Peng.   

Abstract

Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma in humans. The life cycle of HCV is closely associated with the metabolism of lipids, especially very-low-density lipoprotein (VLDL) in hepatocytes. Hepatocyte nuclear factor 4α (HNF4α), the most abundant transcription factor in the liver, regulates the VLDL secretory pathway. However, the effects of HNF4α on the HCV life cycle are unclear. In this study, we investigated the regulatory effects of HNF4α on HCV assembly and secretion. HCV in HNF4α-deficient hepatocytes showed reduced assembly and secretion but unchanged entry and RNA replication. Bezafibrate, a chemical inhibitor of HNF4α, suppressed HCV assembly and secretion. HNF4α downregulation resulted in rearrangement of cytosolic lipid droplets (LDs), as evidenced by the aggregation of large LDs and distorted cytosolic distribution. Phospholipase A2 GXIIB (PLA2GXIIB), an HNF4α-regulated factor involved in VLDL secretion, was found to be crucial in HCV secretion. PLA2GXIIB expression was upregulated in hepatocytes harboring HCV subgenomic replicons or in HCV-infected hepatocytes. This upregulation was transcriptionally controlled in an HNF4α-dependent manner after HCV infection. Furthermore, PLA2GXIIB combined with microsomal triglyceride transfer protein was found to be responsible for the regulation of HNF4α-induced HCV infectivity. These results suggest that HNF4α and its downstream PLA2GXIIB are important factors affecting the late stage of the HCV life cycle and may serve as potential drug targets for the treatment of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173221      PMCID: PMC3911757          DOI: 10.1128/JVI.02068-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C.

Authors:  Naoki Fujita; Masahiko Kaito; Hideaki Tanaka; Shinichiro Horiike; Yukihiko Adachi
Journal:  Am J Gastroenterol       Date:  2004-11       Impact factor: 10.864

2.  Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.

Authors:  N Fujita; M Kaito; M Kai; R Sugimoto; H Tanaka; S Horiike; M Konishi; M Iwasa; S Watanabe; Y Adachi
Journal:  J Viral Hepat       Date:  2006-07       Impact factor: 3.728

Review 3.  Hepatitis C virus host cell entry.

Authors:  Alexander Ploss; Matthew J Evans
Journal:  Curr Opin Virol       Date:  2012-01-04       Impact factor: 7.090

4.  Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus.

Authors:  Gulam H Syed; Aleem Siddiqui
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

Review 5.  Hepatitis C virus: a new class of virus associated with particles derived from very low-density lipoproteins.

Authors:  Jin Ye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05       Impact factor: 8.311

6.  Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Authors:  Jin Ye; Chunfu Wang; Rhea Sumpter; Michael S Brown; Joseph L Goldstein; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

7.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

8.  Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus.

Authors:  Q Dang; D Walker; S Taylor; C Allan; P Chin; J Fan; J Taylor
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

9.  Drosophila HNF4 regulates lipid mobilization and beta-oxidation.

Authors:  Laura Palanker; Jason M Tennessen; Geanette Lam; Carl S Thummel
Journal:  Cell Metab       Date:  2009-03       Impact factor: 27.287

10.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

View more
  16 in total

1.  Hepatitis C Virus Is Released via a Noncanonical Secretory Route.

Authors:  Karen Bayer; Carina Banning; Volker Bruss; Linda Wiltzer-Bach; Michael Schindler
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

2.  An Atlas of Genetic Variation Linking Pathogen-Induced Cellular Traits to Human Disease.

Authors:  Liuyang Wang; Kelly J Pittman; Jeffrey R Barker; Raul E Salinas; Ian B Stanaway; Graham D Williams; Robert J Carroll; Tom Balmat; Andy Ingham; Anusha M Gopalakrishnan; Kyle D Gibbs; Alejandro L Antonia; Joseph Heitman; Soo Chan Lee; Gail P Jarvik; Joshua C Denny; Stacy M Horner; Mark R DeLong; Raphael H Valdivia; David R Crosslin; Dennis C Ko
Journal:  Cell Host Microbe       Date:  2018-08-08       Impact factor: 21.023

3.  Phosphatidylserine-specific phospholipase A1 involved in hepatitis C virus assembly through NS2 complex formation.

Authors:  Min Guo; Rongjuan Pei; Qi Yang; Huang Cao; Yun Wang; Chunchen Wu; Jizheng Chen; Yuan Zhou; Xue Hu; Mengji Lu; Xinwen Chen
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

4.  Endoplasmic reticulum stress links hepatitis C virus RNA replication to wild-type PGC-1α/liver-specific PGC-1α upregulation.

Authors:  Wenxia Yao; Hua Cai; Xinlei Li; Ting Li; Longbo Hu; Tao Peng
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

5.  Vinexin β Interacts with Hepatitis C Virus NS5A, Modulating Its Hyperphosphorylation To Regulate Viral Propagation.

Authors:  Wei Xiong; Jie Yang; Mingzhen Wang; Hailong Wang; Zhipeng Rao; Cheng Zhong; Xiu Xin; Lin Mo; Shujuan Yu; Chao Shen; Congyi Zheng
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

6.  GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion.

Authors:  Longbo Hu; Wenxia Yao; Fang Wang; Xia Rong; Tao Peng
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 7.  Hepatitis C virus life cycle and lipid metabolism.

Authors:  Costin-Ioan Popescu; Laura Riva; Ovidiu Vlaicu; Rayan Farhat; Yves Rouillé; Jean Dubuisson
Journal:  Biology (Basel)       Date:  2014-12-15

Review 8.  Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.

Authors:  Mirjam B Zeisel; Emilie Crouchet; Thomas F Baumert; Catherine Schuster
Journal:  Viruses       Date:  2015-11-02       Impact factor: 5.048

9.  Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway.

Authors:  Jung-Sheng Yu; Wei-Chun Chen; Chin-Kai Tseng; Chun-Kuang Lin; Yao-Chin Hsu; Yen-Hsu Chen; Jin-Ching Lee
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

10.  Cell-death-inducing DFFA-like Effector B Contributes to the Assembly of Hepatitis C Virus (HCV) Particles and Interacts with HCV NS5A.

Authors:  Hua Cai; Wenxia Yao; Leike Li; Xinlei Li; Longbo Hu; Runming Mai; Tao Peng
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.